摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-ethyl 2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate | 94122-76-6

中文名称
——
中文别名
——
英文名称
(Z)-ethyl 2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate
英文别名
ethyl (Z)-2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate;2-hydroxy-5,5-dimethyl-4-oxo-hex-2-enoic acid ethyl ester
(Z)-ethyl 2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate化学式
CAS
94122-76-6
化学式
C10H16O4
mdl
——
分子量
200.235
InChiKey
KAIQXLGAGMBFGI-SREVYHEPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    314.3±42.0 °C(Predicted)
  • 密度:
    1.081±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    (Z)-ethyl 2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate盐酸羟胺 作用下, 以 乙腈 为溶剂, 反应 3.0h, 以91%的产率得到5-叔丁基基-异噁唑-3-甲酸乙酯
    参考文献:
    名称:
    将异恶唑转化为多种恶唑产物的连续流光异构化反应的发展。
    摘要:
    提出了一种连续流动的方法,其通过光化学转座反应将异恶唑直接转化为它们的恶唑对应物。这导致首次报道了利用这种转化来确定其范围和综合实用性的方法。通过这种快速而温和的流动过程,实现了一系列带有不同附件的包括不同杂环部分的各种二取代和三取代的恶唑产物。此外,通过生成克量的选定产品,同时还提供了对可能的中间体的见识,证明了这种方法的鲁棒性。
    DOI:
    10.1021/acs.joc.9b03399
  • 作为产物:
    描述:
    频哪酮草酸二乙酯sodium ethanolate 作用下, 以 乙醇 为溶剂, 反应 4.33h, 以31%的产率得到(Z)-ethyl 2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate
    参考文献:
    名称:
    一系列新型 GluN2C 选择性增强剂的设计、合成和结构-活性关系
    摘要:
    NMDA受体是介导慢速的Ca GluN1和GluN2A-d亚基组成的四聚体复合2+ -兴奋性突触传递的渗透组分。NMDA 受体与广泛的神经系统疾病有关,因此代表了一个重要的治疗靶点。我们在此描述了一系列新型吡咯烷酮,它们选择性地仅增强含有 GluN2C 亚基的 NMDA 受体。测试的最活跃的类似物对重组 GluN2C 受体的选择性是对 GluN2A/B/D 含 NMDA 受体以及 AMPA 和红藻氨酸受体的 100 倍以上。该系列代表了第一类对含二异聚体 GluN2C 的 NMDA 受体具有选择性的变构增效剂。
    DOI:
    10.1021/jm401695d
点击查看最新优质反应信息

文献信息

  • Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
    申请人:Chapal Nicolas
    公开号:US20060223884A1
    公开(公告)日:2006-10-05
    The invention relates to 4-hydroxyisoleucine, isomers, analogs, lactones, salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. More particularly, the invention relates to the use of those compounds in the prevention and treatment of obesity and related syndromes.
    本发明涉及4-羟基异亮氨酸、其同分异构体、类似物、内酯、盐和前药,以及它们的制备过程,以及包含它们的药物组合物。更具体地说,本发明涉及这些化合物在预防和治疗肥胖及相关综合症中的用途。
  • Analogs of 4-hydroxyisoleucine and uses thereof
    申请人:Mioskowski Charles
    公开号:US20060199853A1
    公开(公告)日:2006-09-07
    The invention relates to analogs of 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The analogs of the invention stimulate both glucose uptake and insulin secretion, and may thus be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism, including diabetes mellitus (type 1 and type 2 diabetes), pre-diabetes, and Metabolic Syndrome.
    本发明涉及4-羟基异亮氨酸的类似物,以及它们的内酯、药物可接受的盐和前药,其制备过程,以及包含它们的药物组合物。发明的这些类似物能够刺激葡萄糖摄取和胰岛素分泌,因此可用于预防治疗碳水化合物或脂质代谢紊乱,包括糖尿病(1型和2型糖尿病)、前驱糖尿病和代谢综合征。
  • PYRAZOLE INHIBITORS OF COX-2 AND SEH
    申请人:Hammock Bruce D.
    公开号:US20140038923A1
    公开(公告)日:2014-02-06
    The present invention provides compounds and compositions, e.g., a series of compounds wherein a 1,5-biarylpyrazole group is conjugated to a urea group by a non-cleavable covalent chain, that are useful as dual COX-2/sEH inhibitors. The compounds disclosed herein have activity associated with the arachidonate cascade. The activity of these compounds was demonstrated using a lipopolysaccharide (LPS) induced model of pain in the rat. The compounds of the present invention demonstrated superior anti-allodynic activity as compared to the same dose of celecoxib, i.e., a COX-2 inhibitor, also as compared to the same dose of t-AUCB, i.e., a sEH inhibitor, and also as compared to the co-administered same dose of both celecoxib and t-AUCB. The dual inhibitors of the present invention demonstrate enhanced in vivo anti-allodynic activity in a nociceptive behavioral assay. In addition, the compounds of the present invention also demonstrated to have potent anti-angiogenic effects toward endothelial cells (HUVEC) and inhibit angiogenesis in vitro, ex vivo and in vivo. The dual inhibitors of the present invention also demonstrate anti-angiogenic effect to slow breast tumor growth in vivo.
    本发明提供了化合物和组合物,例如一系列化合物,其中1,5-联苯吡唑基通过不可断裂的共价链与尿素基结合,这些化合物可用作双COX-2/sEH抑制剂。本文披露的化合物具有与花生四烯酸级联相关的活性。这些化合物的活性是使用大鼠脂多糖(LPS)诱导的疼痛模型进行证明的。与同等剂量的Celecoxib(即COX-2抑制剂)以及同等剂量的t-AUCB(即sEH抑制剂)相比,本发明的化合物表现出优越的抗痛觉过敏活性,也与同时给予的Celecoxib和t-AUCB的同等剂量相比。本发明的双重抑制剂在伤害性行为测定中显示出增强的体内抗痛觉过敏活性。此外,本发明的化合物还表现出对内皮细胞(HUVEC)具有强效的抗血管生成作用,并且在体外、体内和体内抑制血管生成。本发明的双重抑制剂还表现出抗血管生成效应,可以减缓体内乳腺肿瘤生长。
  • [EN] HETEROYCLYLPHENYL-AND HETEROCYCLYLPYRIDYL-SUBSTITUTED AZOLECARBOXAMIDES AS HERBICIDES<br/>[FR] AZOLECARBOXAMIDES SUBSTITUES PAR HETEROCYCLYLPHENYLE ET HETEROCYCLYLPYRIDILE
    申请人:DU PONT
    公开号:WO2005040152A1
    公开(公告)日:2005-05-06
    Compounds of Formula (I), and their N-oxides and agriculturally suitable salts, are disclosed which are useful for controlling undesired vegetation : wherein (J) is (J-1), (J-2), (J-3), (J-4), (J-5), (J-6), (J-7), (J-8), or (J-9) ; R5 is a phenyl ring or a 5- or 6-membered heteroaromatic ring which includes at least one heteroatom selected from N, O and S, each ring optionally substituted with one or more substituents selected from R15; or R5 is a 5- or 6-membered partially unsaturated heterocyclic ring which includes at least one heteroatom selected form N, O and S, the ring connected through a nitrogen atom or an sp2 carbon atom to the remainder of Formula (I) and optionally substituted by one or more substituents selected from R16; and R1a, R1b, R2a, R2b, R3, R4, R15, R16, T, U, W, Y and Z are as defined in the disclosure.
    公式(I)的化合物及其N-氧化物和农业适用盐已被披露,可用于控制不受欢迎的植被:其中(J)为(J-1)、(J-2)、(J-3)、(J-4)、(J-5)、(J-6)、(J-7)、(J-8)或(J-9);R5为苯环或含有N、O和S中至少一个杂原子的5-或6-成员杂芳环,每个环可以选择性地取代一个或多个R15所选取的取代基;或者R5为包含至少一个N、O和S中选取的杂原子的5-或6-成员部分不饱和杂环,该环通过氮原子或sp2碳原子连接到公式(I)的其余部分,并可以选择性地取代一个或多个R16所选取的取代基;而R1a、R1b、R2a、R2b、R3、R4、R15、R16、T、U、W、Y和Z的定义如披露中所述。
  • Azolecarboxamide herbicides
    申请人:Armel Russell Gregory
    公开号:US20060069132A1
    公开(公告)日:2006-03-30
    Compounds of Formula I, and their N-oxides and agriculturally suitable salts, are disclosed which are useful for controlling undesired vegetation and R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , T, U, W, Y and Z are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula I and a method for controlling undesired vegetation which involves contacting the vegetation or its environment with an effective amount of a compound of Formula I. Also disclosed are mixtures and compositions comprising a herbicidally effective amount of a compound of Formula Iz wherein J, R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , T, U, W, Y and Z are as defined in the disclosure; and an effective amount of another herbicide or herbicide safener. Also disclosed is a method for selectively controlling undesired vegetation in a crop that involves contacting the locus of a crop with an effective amount of a compound of Formula Iz and a effective amount of a safener.
    公开了化学式I的化合物及其N-氧化物和适用于农业的盐,其可用于控制不良杂草,其中R1a,R1b,R1c,R2a,R2b,R3,R4,R5,T,U,W,Y和Z如披露所定义。还公开了含有化学式I的化合物的组合物以及一种控制不良杂草的方法,该方法涉及将化合物I与植物或其环境的有效量接触。还公开了混合物和组合物,包括化学式Iz的除草有效量,其中J,R1a,R1b,R1c,R2a,R2b,R3,R4,R5,T,U,W,Y和Z如披露所定义;以及另一种除草剂或除草剂安全剂的有效量。还公开了一种用于选择性控制作物中不良杂草的方法,该方法涉及将化学式Iz的有效量和安全剂的有效量与作物的部位接触。
查看更多